FDA CLEARS ISOFOL’S IND APPLICATION TO START CLINICAL PROGRAM WITHIN COLORECTAL CANCER WITH MODUFOLIN®
Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared Isofol’s investigational new drug (IND) application […]
News
ISOFOL MEDICAL PRESENT AT AKTIETORGET INVESTOR MEETING
Isofol Medical AB presented at the AktieTorget investor meeting on Wednesday, October 5. This was a meeting arranged by SvD
ISOFOL MEDICAL HAS SUCCESSFULLY ADVANCED TO THE NEXT DOSE LEVEL OF MODUFOLIN® IN A PHASE I/II CLINICAL TRIAL IN COLORECTAL CANCER.
Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with 5-FU and oxaliplatin or
ISOFOL MEDICAL SHARE ISSUE OVERSUBSCRIBED, SECURING OVER SEK 39 MILLION TO STRENGTHEN THE ONGOING PHASE II CLINICAL DEVELOPMENT PROGRAM OF MODUFOLIN®
Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology, will use the investment